India's pharmaceutical industry is weighing the implications of new U.S. tariffs on imported medicines that could significantly reduce export volumes.

These measures matter because India is a primary supplier of generic drugs to the U.S. market. The proposed tariffs are designed to force a shift in manufacturing back to American soil by making imports more expensive, which could disrupt global supply chains and increase drug costs for consumers.

Donald Trump said he has announced a phased tariff plan for imported generic drugs, keeping tariffs at 0% for two years [1] before imposing a 100% duty in August 2028 [1] and 200% thereafter in 2029 [1].

Industry bodies, including the Indian Pharmaceutical Alliance, are currently analyzing how these costs will affect the viability of their operations. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, said the industry is studying the announcement while remaining engaged with U.S. authorities.

Some analysts suggest the move could lead to a three-fold rise in U.S. drug-making costs for Indian exporters [2]. This financial pressure may force companies to consider investing in U.S.-based facilities, though such a transition faces significant hurdles. An unnamed analyst said higher cost of operations is a major deterrent at the moment [3].

There is currently a lack of consensus regarding the exact scope of the tariffs. Some reports indicate the duties target imported generic drugs [1], while other sources suggest the tariffs hit patented medicines rather than low-cost generics.

Representatives from the industry have held meetings in Mumbai and Manila to discuss strategic responses to the policy. The goal remains to maintain market access while navigating the phased increase in duties over the next few years.

“The industry is studying the announcement while remaining engaged with US authorities.”

The U.S. strategy represents a pivot toward pharmaceutical protectionism and reshoring. By implementing a phased tariff schedule, the U.S. government is providing a two-year window for Indian firms to either absorb costs or relocate production. If Indian exporters cannot find a way to mitigate a potential 3x increase in costs, the U.S. may see a decrease in generic drug availability and a rise in pharmacy prices before domestic capacity can be fully established.